The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tivozanib (T) as first-line (1L) treatment of metastatic renal cell carcinoma (mRCC): A real-world outcome review in North-West of England (NWE), UK.
 
Jonathan Heseltine
No Relationships to Disclose
 
Jennifer Allison
Honoraria - Bristol-Myers Squibb
Travel, Accommodations, Expenses - EUSA Pharma
 
Sam Wong
No Relationships to Disclose
 
Kellati Prasad
No Relationships to Disclose
 
Helen Wong
No Relationships to Disclose
 
Zhu Oong
No Relationships to Disclose
 
Natalie Charnley
No Relationships to Disclose
 
Andrea Law
No Relationships to Disclose
 
Omi Parikh
No Relationships to Disclose
 
Manon Rhys Pillai
No Relationships to Disclose
 
Tom Waddell
Honoraria - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Ipsen; Merck Sharp & Dohme; Pfizer; Roche
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EUSA Pharma; Ipsen
 
Richard Griffiths
No Relationships to Disclose
 
Shien Chow
No Relationships to Disclose